Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel...

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Limited data exist on omalizumab's efficacy and impact on airway remodeling in oral corticosteroid (OC)-dependent asthma.
• Severe asthma patients on OCs face challenges with disease burden and airway structural changes.

Purpose of the Study:

• To evaluate omalizumab as a corticosteroid-sparing therapy in severe asthma.
• To assess omalizumab's ability to inhibit airway remodeling and reduce disease burden, including lung function impairment and exacerbations.

Main Methods:

• A randomized open-label study comparing omalizumab plus standard care versus standard care alone in OC-dependent severe asthma patients.
• Primary endpoint: change in monthly OC dose. Secondary endpoints: spirometry, FeNO, exacerbations, and airway remodeling via bronchial biopsies (transmission electron microscopy).

Main Results:

• Omalizumab group showed a significant reduction in mean monthly OC dose (-148.1 mg) and a 75% OC withdrawal rate compared to 7.7% in the control group.
• Omalizumab slowed FEV1 loss, decreased FeNO, reduced exacerbations by 54%, and significantly decreased basement membrane thickness and intercellular spaces in airway biopsies.
• The treatment was well-tolerated, with qualitative improvements observed in the omalizumab group.

Conclusions:

• Omalizumab demonstrates significant corticosteroid-sparing effects in OC-dependent asthma.
• The therapy is associated with improved clinical outcomes and correlates with bronchial epithelial repair and airway remodeling reversal.
• Reversibility of airway remodeling is possible in OC-dependent asthma, challenging traditional views on irreversible airway obstruction.